Data Year:

For its 2024 fiscal year, Lyra Therapeutics, Inc., listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In MFG Durable industry
Maria Palasis Ph.D.
President and Chief Executive Officer
Total Compensation $3,732,197 View details Pay Rank By Title In MFG Durable industry #461 View more
Jason Cavalier
Chief Financial Officer and Treasurer
Total Compensation $1,303,960 View details Pay Rank By Title In MFG Durable industry #472 View more
Richard Nieman M.D.
Former Chief Medical Officer
Total Compensation $1,354,191 View details Pay Rank By Title In MFG Durable industry #112 View more
Harlan W. Waksal M.D.
Executive Chairman
Total Compensation $2,796,609 View details Pay Rank By Title In MFG Durable industry #60 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at Lyra Therapeutics, Inc. as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. Lyra Therapeutics, Inc. income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. Lyra Therapeutics, Inc. annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Maria Palasis Ph.D.
President and Chief Executive Officer
Total Cash $812,500 Equity $2,855,209 Other $64,488 $3,732,197
Jason Cavalier
Chief Financial Officer and Treasurer
Total Cash $577,777 Equity $657,259 Other $68,924 $1,303,960
Richard Nieman M.D.
Former Chief Medical Officer
Total Cash $323,116 Equity $633,239 Other $397,836 $1,354,191
Harlan W. Waksal M.D.
Executive Chairman
Total Cash $400,000 Equity $2,365,731 Other $30,878 $2,796,609
For its 2024 fiscal year, Lyra Therapeutics, Inc., listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
C. Ann Merrifield Total Cash $61,419
Edward T. Anderson Total Cash $11,875
James R. Tobin Total Cash $100,669
Konstantin Poukalov Total Cash $46,104
Michael Altman Total Cash $46,104
Nancy Snyderman, M.D., FACS Total Cash $62,732
W. Bradford Smith Total Cash $72,169
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.